Please use this identifier to cite or link to this item:
Title: Secondary acute myelogenous leukemia in patients with retinoblastoma - Is chemotherapy a factor?
Authors: Gombos, Dan S.
Hungerford, John
Abramson, David H.
Kingston, Judith
Chantada, Guillermo
Dunkel, Ira J.
Antoneli, Celia B. G.
Greenwald, Mark
Haik, Barret G.
Leal, Carlos A.
Medina-Sanson, Aurora
Schefler, Amy C.
Veerakul, Gavivann
Wieland, Regina
Bornfeld, Norbert
Wilson, Mathew W.
Yu, Christopher Bing On
MD Anderson Canc Ctr
Barts & London Natl Hlth Serv Trust
Moorfields Eye Hosp
Mem Sloan Kettering Canc Ctr
Hosp JP Garrhan
Universidade Federal de São Paulo (UNIFESP)
Univ Chicago
Univ Tennessee
St Jude Childrens Hosp
Pediat Natl Inst
Hosp Infantil Mexico Dr Federico Gomez
Miller Sch Med
Mahidol Univ
Univ Essen Gesamthsch
Chinese Univ Hong Kong
Issue Date: 1-Jul-2007
Publisher: Elsevier B.V.
Citation: Ophthalmology. New York: Elsevier B.V., v. 114, n. 7, p. 1378-1383, 2007.
Abstract: Purpose: To describe a series of patients with secondary acute myelogenous leukemia (sAML) and retinoblastoma (RB).Design: Retrospective observational cases series.Participants: Ocular and pediatric oncologists at referral centers in Europe and the Americas and the RB databases at the National Institutes of Health and the Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center.Methods: Physician survey, retrospective database review, and literature search.Main Outcome Measures: History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia, French-American-British (FAB) subtype, and current status of patient (alive or dead).Results: Fifteen patients with sAML were identified; 13 occurred in childhood. Mean latent period from RB to AML diagnosis was 9.8 years (median, 42 months). Nine cases were of the M2 or M5 FAB subtypes. Twelve patients (79%) had received chemotherapy with a topoisomerase II inhibitor, 8 (43%) had received chemotherapy with an epipodophyllotoxin. Ten children died of their leukemia.Conclusions: Acute myelogenous leukemia is a rare secondary malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy. Additional studies are needed to assess potential risk factors contributing to sAML development in this cohort.
ISSN: 0161-6420
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.